Los puntos clave no están disponibles para este artículo en este momento.
PTTCP is frequently associated with severe bleeding, which is a risk factor for graft loss and death. Those findings suggest that the risk/benefit ratio of antiplatelet or anticoagulation therapies should be systemically evaluated for PTTCP patients.
Léonard et al. (2025) studied this question.